Baudax Bio, Inc.

Good morning and welcome to the BOTOX Value Full Year 2020 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session and instructions will be given at that time. As a reminder, this conference is being recorded at the company's request. I would now like to turn the call over to Ms. Claudia Steislinger, Investor Relations. Ma'am, you may begin.

Good morning, and thank you for joining us on today's conference call to discuss BadoxBio's full year 2020 financial results. This is Claudia Steislinger, and I am joined today by Jerry Henwood, President and Chief Executive Officer, John Harlow, Chief Commercial Officer, and Ryan Lake, Chief Financial Officer. On today's call, Jerry will provide some introductory remarks and a business update. John will discuss the progress made on the commercial launch of Angesso, And Ryan will discuss the financial highlights. Following today's prepared remarks from Jerry, John, and Ryan, we will open the call for questions. Earlier this morning, we issued a press release detailing our financial results for the full year 2020. The press release, along with the slide presentation that we will reference for today's call, is available on the events page of the news and investors section of our website at badaxbio.com. Please note the slides for today's presentation are viewer-controlled. Before we begin our formal comments, I'll remind you that various remarks we make today constitute forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our financial outlook. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our expectations and forecasts, and can be identified by words such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will, and other words of similar meaning. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements. The ongoing economic and social consequences of the COVID-19 pandemic including any adverse impact on the commercial launch of Angesso or disruption in supply chain, our ability to maintain regulatory approval for Angesso, our ability to successfully commercialize Angesso, the acceptance of Angesso by the medical community, including physicians, patients, healthcare providers, and hospital formularies, our ability and that of our third-party manufacturers to successfully scale up our commercial manufacturing process for Angesso, our ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for Ingeso, and our ability to raise future financing for the continued product development and Ingeso commercialization. This list of important factors is not all-inclusive. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the risk factors and the management's discussion and analysis section of BodexBio's annual report on Form 10-K for the fiscal year ended December 31, 2019, and any other quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the day of this call, February 16, 2021, and we undertake no obligation to update any forward-looking statements we may make on this call. on account of new information, future events, or otherwise. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially. I would now like to turn the call over to Jerry Henwood. Jerry?

Thank you, Claudia, and good morning, everyone. We hope those of you who are joining us today are keeping safe. And we'd like to now turn to giving you an update on Baudax Bio and Antifo status. If you could turn to slide five in the presentation that is both on our website and that has been 8K. We are making progress in spite of the pace being impacted by our current pandemic. Unfortunately, it is still affecting, had gone through a little bit of a lull, came back with a roar in the fall, as you know, and is still present. although we hope with vaccinations and with some abatement in infection rates that we'll see further progress. But it has disrupted formulary meetings and elective surgery schedules on a continuing basis. The Q4 vials sold grew by 58% versus the third quarter in spite of these COVID headwinds. And our average account purchase has increased by 63%. More than half of our accounts reordered in 2020, and that increased to 60% in the fourth quarter. As of January of this year, Ingesto is on contract with the three largest GPOs in the United States, Vizient, Premier, and Health Trust. I'd like to now turn the meeting back to John to give us more color and more detail. on the commercial launch highlights. John?